EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

P2Y12 Receptor Inhibitor for Antiaggregant Therapies: From Molecular Pathway to Clinical Application

Francesco Nappi iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25147575 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Francesco Nappi. Beteiligte Einrichtung: Department of Cardiac Surgery, Centre Cardiologique du Nord, 93200 Saint-Denis, France. Hauptthemen laut MEDLINE: Purinergic P2Y Receptor Antagonists, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Platelets play a significant role in hemostasis, forming plugs at sites of vascular injury to limit blood loss. However, if platelet activation is not controlled, it can lead to thrombotic events, such as myocardial infarction and stroke. To prevent this, antiplatelet agents are used in clinical settings to limit platelet activation in patients at risk of arterial thrombotic events. However, their use can be associated with a significant risk of bleeding. An enhanced comprehension of platelet signaling mechanisms should facilitate the identification of safer targets for antiplatelet therapy. Over the past decade, our comprehension of the breadth and intricacy of signaling pathways that orchestrate platelet activation has expanded exponentially. Several recent studies have provided further insight into the regulation of platelet signaling events and identified novel targets against which to develop novel antiplatelet agents. Antiplatelet drugs are essential in managing atherothrombotic vascular disease. The current antiplatelet therapy in clinical practice is limited in terms of safety and efficacy. Novel compounds have been developed in response to patient variability and resistance to aspirin and/or clopidogrel. Recent studies based on randomized controlled trials and systematic reviews have definitively demonstrated the role of antiplatelet therapy in reducing the risk of cardiovascular events. Antiplatelet therapy is the recommended course of action for patients with established atherosclerosis. These studies compared monotherapy with a P2Y12 inhibitor versus aspirin for secondary prevention. However, in patients undergoing percutaneous coronary intervention, it is still unclear whether the efficacy of P2Y12 inhibitor monotherapy after a short course of dual antiplatelet therapy depends on the type of P2Y12 inhibitor. This paper focuses on the advanced-stage evaluation of several promising antiplatelet drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purinergic P2Y Receptor AntagonistsPlatelet Aggregation InhibitorsHumansReceptors, Purinergic P2Y12Blood PlateletsSignal TransductionPlatelet ActivationAnimals

Stichwörter der Autor:innen

P2Y12 inhibitorantiplatelet drugsbleedingplateletsthrombosis

Substanzen

Purinergic P2Y Receptor AntagonistsPlatelet Aggregation InhibitorsReceptors, Purinergic P2Y12

Autor:innen und Institutionen

  • Department of Cardiac Surgery, Centre Cardiologique du Nord, 93200 Saint-Denis, France.

ORCID-Profile: Francesco Nappi

Zitieren

APA

Nappi, F. (2024). P2Y12 Receptor Inhibitor for Antiaggregant Therapies: From Molecular Pathway to Clinical Application. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147575

Vancouver

Nappi F. P2Y12 Receptor Inhibitor for Antiaggregant Therapies: From Molecular Pathway to Clinical Application. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147575

BibTeX
@article{Nappi2024,
  author = {Nappi, Francesco},
  title = {P2Y12 Receptor Inhibitor for Antiaggregant Therapies: From Molecular Pathway to Clinical Application},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25147575}
}
Kostenlos starten →